Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 83 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
This article has been cited by
1
Md. Akil Hossain,Rokeya Pervin
.2018;()455
[DOI]
2The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice
Anne Řrgaard,Jens J. Holst
Diabetologia.2017;60(9)1731
[DOI]
3Clinical Characteristics and Satisfaction of Liraglutide Treatment among Patients with Type 2 Diabetes: A Prospective Study
Ayman A Al Hayek,Asirvatham A Robert,Mohamed A Al Dawish
Clinical Medicine Insights: Endocrinology and Diabetes.2019;12(9)117955141983493
[DOI]
4GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
Andrei C. Sposito,Otávio Berwanger,Luiz Sérgio F. de Carvalho,José Francisco Kerr Saraiva
Cardiovascular Diabetology.2018;17(1)117955141983493
[DOI]
5Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes
Leigh Perreault,Helena Rodbard,Virginia Valentine,Eric Johnson
Advances in Therapy.2019;36(2)265
[DOI]
6Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
Dongzhe Hong,Lei Si,Minghuan Jiang,Hui Shao,Wai-kit Ming,Yingnan Zhao,Yan Li,Lizheng Shi
PharmacoEconomics.2019;37(6)777
[DOI]
7Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease
Sebastian Niezen,Humberto Diaz del Castillo,Lumen A. Mendez Castaner,Alessia Fornoni
Endocrinology, Diabetes & Metabolism.2019;37(6)e00072
[DOI]
8The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy
Jerry Meece
Advances in Therapy.2017;34(3)638
[DOI]
9A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes
Neil Webb,Michelle Orme,Michal Witkowski,Rie Nakanishi,Jakob Langer
Diabetes Therapy.2018;9(3)973
[DOI]
10Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy
Philip D. Home,Bo Ahrén,Jane E.B. Reusch,Marc Rendell,Peter N. Weissman,Deborah T. Cirkel,Diane Miller,Philip Ambery,Molly C. Carr,Michael A. Nauck
Diabetes Research and Clinical Practice.2017;131(3)49
[DOI]
11Body Weight Considerations in the Management of Type 2 Diabetes
Caroline M. Apovian,Jennifer Okemah,Patrick M. O’Neil
Advances in Therapy.2019;36(1)44
[DOI]
12Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease
Ying Liu,Xia Jiang,Xin Chen
Lipids in Health and Disease.2017;16(1)44
[DOI]
13GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective
Roy Rasalam,John Barlow,Mark Kennedy,Pat Phillips,Alan Wright
Diabetes Therapy.2019;16(1)44
[DOI]
14Emerging technologies to achieve oral delivery of GLP-1 and GLP-1 analogs for treatment of type 2 diabetes mellitus (T2DM)
Shengwu Ma,Liang We,Hongji Yang,Shaoping Deng,Anthony M. Jevnikar
Canadian Journal of Biotechnology.2017;1(1)1
[DOI]
15A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
Irene Romera,Ana Cebrián-Cuenca,Fernando Álvarez-Guisasola,Fernando Gomez-Peralta,Jesús Reviriego
Diabetes Therapy.2019;10(1)5
[DOI]
16Lixisenatide: A New Option for Managing Type 2 Diabetes
Jonathan S. Newsome
Journal of Pharmacy Technology.2017;33(5)195
[DOI]
17Selective beneficial cardiometabolic effects of vertical sleeve gastrectomy are predominantly mediated through glucagon-like peptide (GLP-1) in Zucker diabetic fatty rats
Sunil Kumar,Raymond Lau,Thomas Palaia,Christopher Hall,Jenny Lee,Keneth Hall,Collin E. Brathwaite,Louis Ragolia
Annals of Medicine and Surgery.2016;12(5)65
[DOI]
18Long-lasting Glucagon-like Peptide 1 Analogue Exendin-4 Ameliorates the Secretory and Synthetic Function of Islets Isolated From Severely Scalded Rats
Dongxu Zhao,Li Ma,Chuanan Shen,Dawei Li,Wenfeng Cheng,Yuru Shang,Zhaoxing Liu,Xin Wang,Kai Yin
Journal of Burn Care & Research.2018;39(4)545
[DOI]
19GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis
Marco Castellana,Angelo Cignarelli,Francesco Brescia,Luigi Laviola,Francesco Giorgino
Diabetes/Metabolism Research and Reviews.2019;35(1)e3082
[DOI]
20Narrative review of the effects of antidiabetic drugs on albuminuria
Habib Yaribeygi,Stephen L. Atkin,Niki Katsiki,Amirhossein Sahebkar
Journal of Cellular Physiology.2019;234(5)5786
[DOI]
21Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients
Lima Lawrence,Venu Menon,Sangeeta Kashyap
Current Cardiology Reports.2018;20(8)5786
[DOI]
22The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease
Carlota Recio,Francesco Maione,Asif J. Iqbal,Nicola Mascolo,Vincenzo De Feo
Frontiers in Pharmacology.2017;7(8)5786
[DOI]
  Feedback 
  Subscribe 

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal